HIV Testing: Window Periods, Accuracy, and What Results Mean

HIV (human immunodeficiency virus) attacks the immune system — specifically CD4 T cells, the infection-fighting cells that help the body defend itself. Without treatment, HIV gradually weakens that defense. Untreated infection typically moves through chronic HIV and, at the most advanced stage, to AIDS (acquired immunodeficiency syndrome).

HIV spreads through specific bodily fluids: blood, semen, pre-seminal fluid, rectal fluids, vaginal fluids, and breast milk. In the United States, the primary routes are sexual contact, sharing injection equipment, and during pregnancy, birth, or breastfeeding when the virus is not suppressed. HIV is not transmitted through casual contact, saliva, sweat, or shared toilet seats. (Source: CDC.)

Many people notice symptoms soon after HIV enters the body — and many others do not. According to CDC, most people who develop symptoms get a flu-like illness within 2 to 4 weeks after infection: this early stage is called acute HIV infection, and symptoms can include fever, chills, rash, night sweats, sore throat, muscle aches, fatigue, and swollen lymph nodes for a few days to several weeks. They are easy to mistake for another illness — having them does not mean a person has HIV, and having none does not rule it out.

After acute infection, HIV enters a chronic stage (clinical latency). People here often feel completely well — CDC notes it can last a decade or longer without treatment — while the virus reproduces at low levels. Because chronic HIV is usually symptom-free, testing is the only reliable way to know one's status.

No HIV test can detect the virus on the day of an exposure. Every test type has a window period — the time between a possible exposure and when that test can reliably detect HIV. Choosing a test means matching it to how recent the exposure was, and reading any negative result against that timing.

CDC's current guidance describes four categories. A laboratory antigen/antibody test (often called 4th-generation, drawn from a vein) can usually detect HIV 18 to 45 days after exposure. A nucleic acid test (NAT), which looks for the virus itself, can usually detect HIV 10 to 33 days after exposure. A rapid antigen/antibody finger-stick test can usually detect HIV 18 to 90 days after exposure. Antibody-only tests — including most rapid tests and self-tests — can usually detect HIV 23 to 90 days after exposure.

Accuracy and window always travel together. A negative result taken before the window has passed cannot rule out HIV; that is a limitation of timing, not a broken test. CDC's advice is direct: if you test after a possible exposure and the result is negative, get tested again after the window period for the test you took. Once the window for that test type has closed, a negative result is meaningful.

Symptoms matter here too: flu-like illness that might be acute HIV — especially within a few weeks of a possible exposure — may lead a clinician to order an HIV RNA test alongside standard screening, because RNA detection can return results earlier than waiting for the immune response antibody tests rely on.

An HIV diagnosis is the starting point for care, not an endpoint. Antiretroviral therapy (ART) reduces the amount of virus in the blood; taken as prescribed, it can bring viral load so low that standard tests cannot detect it — what CDC defines as an undetectable viral load, with viral suppression more broadly defined as fewer than 200 copies per milliliter of blood.

This is where U=U comes in. Undetectable = Untransmittable is how CDC frames a well-established finding: a person living with HIV who takes treatment as prescribed and maintains an undetectable viral load does not transmit HIV to sexual partners. That conclusion rests on landmark studies of mixed-status couples — HPTN 052, PARTNER, PARTNER 2, and Opposites Attract — in which no linked sexual transmissions were observed while the partner with HIV was virally suppressed. U=U is one of the most positive, concrete reasons to test and stay in care.

Without treatment, HIV typically progresses: CD4 counts fall and the immune system becomes vulnerable to opportunistic infections. AIDS is the late stage of that progression, and it is far less common today because treatment works. Earlier diagnosis changes the trajectory — treatment keeps people healthy, and sustained viral suppression means sexual transmission does not occur.

CDC's National HIV Surveillance System reported 39,201 HIV diagnoses in the United States and 6 territories and freely associated states in 2023 (provisional, with a 12-month reporting lag). A separate CDC estimate puts new HIV infections at about 31,800 in 2022. Diagnoses and new infections are different measures: diagnoses reflect both underlying transmission and variations in testing practices, which is why CDC cautions against equating the two.

For local context, the staged CDC 2023 metro dataset used across this site shows a mean HIV diagnosis rate of 14.42 per 100,000 population across the 100 largest U.S. metro areas, with a standard deviation of 8.03. One important caveat: these metro figures are diagnosis rates — not prevalence. They count people newly diagnosed in each metro area; they do not measure how many people are living with HIV there. Metro-level prevalence data are not part of this dataset.

HIV screening is routinely performed in laboratories: a blood draw at a participating facility, processed by a certified lab. Many people have HIV testing covered by insurance as part of routine care or an STI evaluation; others prefer self-pay lab testing, which keeps the order and results inside a confidential patient portal rather than routing a claim through an insurer — a priority for some when privacy matters.

STDcheck's HIV testing menu follows the same clinical logic as CDC's guidance. The standard lab-based screening option uses antigen/antibody detection, matching the 4th-generation category above (18- to 45-day window). For people testing sooner after a possible exposure, an HIV RNA early-detection option looks for viral genetic material directly — the same detection principle as CDC's NAT category (10- to 33-day window). A very recent exposure usually calls for RNA-based testing; exposures further in the past can be assessed with standard antigen/antibody screening.

One practical note: testing decisions belong with a healthcare professional, and every screening result should be confirmed and interpreted in a clinical context. This page is educational and is not a substitute for medical advice.

Common questions about HIV test timing, accuracy, and what results can and cannot say.